Literature DB >> 3476805

[Detection of nephrotoxicity of human alpha 2b interferon with special reference to the analysis of urine enzymes in patients with chronic myeloid leukemia].

E Kurschel, U Metz-Kurschel, W Hofmann, N Niederle.   

Abstract

The nephrotoxic potential of alpha-interferon (IFN alpha-2b) was analysed in 21 patients with chronic myeloid leukemia. As particularly sensitive parameters in the detection of subclinical renal injury we measured the excretion of the following urinary enzymes: lactate dehydrogenase (LDH), gamma-glutamyltransferase (GGT), leucine arylaminidase (LAP), beta-galactosidase (GAL) and N-acetyl-beta-glucosaminidase (NAG). Additionally, protein excretion and urinary sediment were analysed. In 18 of 21 patients a significant increase in the excretion of LDH, LAP, GGT and NAG was found, in 6 patients there was an additional rise in the output of GAL. Eleven patients developed proteinuria up to 2 g/l, one patient excreted up to 9 g/l. Enzymuria and protein excretion decreased in all patients after reduction of the IFN alpha-2b dosage and disappeared in two patients following cessation of therapy. The high incidence of nephrotoxic events in patients with CML during IFN alpha-2b therapy might be mostly due to immunological or substance-specific effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3476805     DOI: 10.1007/BF01875502

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  19 in total

1.  Nephrotic syndrome during treatment with interferon.

Authors:  K Sriskandan; D E Tee; K W Pettingale
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-25

2.  Gel gradient electrophoresis, isoelectric focusing and two-dimensional techniques in horizontal, ultrathin polyacrylamide layers.

Authors:  A Görg; W Postel; R Westermeier; E Gianazza; P G Righetti
Journal:  J Biochem Biophys Methods       Date:  1980-11

3.  Severity of glomerulonephritis induced in different strains of suckling mice by infection with lymphocytic choriomeningitis virus: correlation with amounts of endogenous interferon and circulating immune complexes.

Authors:  D Woodrow; P Ronco; Y Riviere; J Moss; I Gresser; J C Guillon; L Morel-Maroger; J C Sloper; P Verroust
Journal:  J Pathol       Date:  1982-12       Impact factor: 7.996

4.  Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides.

Authors:  S D Averbuch; H A Austin; S A Sherwin; T Antonovych; P A Bunn; D L Longo
Journal:  N Engl J Med       Date:  1984-01-05       Impact factor: 91.245

5.  Further studies on the inhibition of lymphocytic choriomeningitis-induced glomerulonephritis by antiinterferon globulin. Circulating immune complexes and ultrastructural studies.

Authors:  P Ronco; D Woodrow; Y Rivière; J Moss; P Verroust; J C Guillon; I Gresser; J C Sloper; L Morel-Maroger
Journal:  Lab Invest       Date:  1980-07       Impact factor: 5.662

6.  Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study.

Authors:  G Abdulhay; P J DiSaia; J A Blessing; W T Creasman
Journal:  Am J Obstet Gynecol       Date:  1985-06-15       Impact factor: 8.661

7.  Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients.

Authors:  P Kramer; F W ten Kate; A B Bijnen; J Jeekel; W Weimar
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

8.  [alpha 2-interferon: preliminary treatment results in chronic myeloid leukemia].

Authors:  N Niederle; O Kloke; C Doberauer; R Becher; D W Beelen; C G Schmidt
Journal:  Dtsch Med Wochenschr       Date:  1986-05-16       Impact factor: 0.628

9.  Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.

Authors:  M Talpaz; K B McCredie; G M Mavligit; J U Gutterman
Journal:  Blood       Date:  1983-09       Impact factor: 22.113

10.  Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results.

Authors:  K A Foon; A E Maluish; P G Abrams; S Wrightington; H C Stevenson; A Alarif; M F Fer; W R Overton; M Poole; E F Schnipper
Journal:  Am J Med       Date:  1986-03       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.